Most Recent
The High Court will weigh in on the relevance of reputation in passing off claims, taking up an appeal by Bed Bath N’ Table of a finding that rival retailer House did not engage in misleading and deceptive conduct in setting up its Bed & Bath stores.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis' appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
The High Court won't hear Bayer's appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company's claim the decision has "profound" consequences for drug R&D.
Otsuka Pharmaceuticals is challenging a decision revoking its patent for an injectable version of antipsychotic drug Abilify.
Generic drug maker Sun Pharma has succeeded in invalidating Otsuka Pharmaceutical’s patent for an injectable, controlled release form of the Japanese drug maker's top-selling antipsychotic Abilify.
Energy company AGL is fighting a $25 million penalty imposed by a court for continuing to deduct payments from hundreds of welfare recipients after their accounts were closed.
The Federal Court has slapped non-bank lender Firstmac with an $8 million penalty, the second doled out in ASIC proceedings for violations of the new design and distribution obligations.
Energy provider AGL has been slapped with a $25 million penalty after it continued to deduct payments from around 500 welfare recipients after they had closed their accounts.
Home retailer Bed Bath N’ Table has asked the High Court to reverse a Full Court judgment that found retailer House did not engage in misleading and deceptive conduct in setting up its Bed & Bath stores.
US animal drug manufacturer Zoetis has lost its challenge a ruling that chucked out three of its patents for a single-dose vaccine to protect pigs from enzootic pneumonia.